Dr. Madsen obtained his Ph.D. in Biomedical Science from the University of Texas Health Science Center, MD Anderson Cancer Center. He obtained his post-doctoral training at the Albert Einstein College of Medicine and then at the Walter Reed Army Institute of Research. There he developed liposome-base vaccine technology in collaboration with Medimmune, Inc. He then joined EntreMed, Inc., focusing on the development of anti-angiogenic/anti-cancer small molecules and biologics. Subsequently, at SAIC Frederick, Inc., he was Director of both Outsourcing and Manufacturing for the Vaccine Clinical Materials Program (VCMP) Vaccine Pilot Plant, where plasmid DNA- and adenoviral vector-based vaccines were manufactured under cGMPs for the NIAID/Vaccine Research Center. He then joined Novavax, Inc., a biotech focusing on the development of vaccines against Influenza and Respiratory Syncytial Virus (RSV), based on Virus-Like Particle (VLP) platform vaccine technology. There he was responsible for process development, clinical manufacturing, and manufacturing collaborations. He was a key member of the team that secured a contract award valued at up to $179 million by BARDA for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic influenza. He is an inventor on ten patents.